Regeneron gets Libtayo approval in Japan for advanced cervical cancer
Regeneron Pharmaceuticals has secured the approval of the Japanese Ministry of Health, Labor and Welfare (MHLW) to manufacture and market the company’s Libtayo (cemiplimab) for advanced or recurrent cervical cancer. Libtayo is a type of immunotherapy intended for the treatment of patients with advanced or recurrent cervical cancer whose disease progressed after chemotherapy. The approval […]